60 Degrees Pharmaceuticals, Inc.

Report primary and secondary endpoint results for the severe babesiosis study

Deadline not yet reached (96 days left)

Announced: 6 Oct 2026
Due: 31 Jan 2027

Deadline
Met
Late
Not met
Today

What the company said

“The Company plans to unblind the study and report its primary and secondary endpoint results in January 2027”

Source60 Degrees Pharmaceuticals, Inc. Form 8-K press release, 2026-10-06
Archived copyWayback Machine snapshot
FilingSEC filing index
Deadline as statedin January 2027
Deadline used31 Jan 2027, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-SXTP-005066
Cite as https://keptindex.org/c/KI-C-2026-SXTP-005066/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Jan 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: severe babesiosis study results
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you 60 Degrees Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-SXTP-005066 · Corrections policy